Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development.
- SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development.
- Prior to that, he held senior scientist positions at Ion Torrent and Nanosphere.
- “Martin is an experienced industry leader whose deep expertise in chemistry and nanoengineering will not only broaden our team’s skillset, but also increase the depth of our R&D leadership bench,” said Subra Sankar, Ph.D., Senior Vice President of Product Development at Nautilus.
- “His success leading a broad range of important product development initiatives – from early feasibility experiments to successful product launches – will be instrumental as we ready Nautilus’ platform for launch next year.”